Management of Autoimmune Disease in Patients Using Subcutaneous Lecanemab for Dementia

Pre-Treatment Assessment

The National Comprehensive Cancer Network recommends performing comprehensive evaluation of autoimmune disease status, including disease activity markers and organ involvement, before initiating lecanemab 1
Assess baseline immunosuppressive regimen and determine if adjustments are needed prior to lecanemab initiation, as recommended by the National Comprehensive Cancer Network 1

Regular clinical assessments are necessary to monitor for both autoimmune disease flares and lecanemab-related adverse events, according to the National Comprehensive Cancer Network 1
More frequent laboratory monitoring of autoimmune markers and inflammatory parameters than standard protocols is recommended 2

For mild autoimmune flares without significant organ involvement, consider continuing lecanemab while adjusting immunosuppressive therapy, as suggested by the National Comprehensive Cancer Network 1
For severe flares with major organ involvement, permanently discontinue lecanemab and initiate high-dose corticosteroids, according to the National Comprehensive Cancer Network and the Journal of Clinical Oncology 1, 3

For patients with pre-existing autoimmune neurologic conditions, consider neurology consultation before initiating lecanemab, as recommended by the Journal of Clinical Oncology 3
If neurologic symptoms worsen, immediately hold lecanemab and obtain MRI to distinguish between ARIA and autoimmune flare, according to the Journal of Clinical Oncology 3

Monitor complete blood count regularly to detect neutrophilia or lymphopenia 2
For grade 3-4 lymphopenia, consider Pneumocystis jirovecii prophylaxis and CMV screening 2

Patients with multiple autoimmune conditions may require more complex management and more frequent monitoring, as recommended by the National Comprehensive Cancer Network 1
Consider non-pharmacological interventions to reduce fall risk, as suggested by Praxis Medical Insights 4

Failing to distinguish between autoimmune disease flare and lecanemab-related adverse events, which may present with similar symptoms, is a pitfall to avoid, according to the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2
Overlooking the increased risk of infection in patients on both immunosuppressants and lecanemab is another pitfall to avoid, as recommended by Praxis Medical Insights 2
Not considering drug interactions between immunosuppressants and other medications needed for dementia management is a pitfall to avoid, according to the American Academy of Family Physicians 5